Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS)
A legfontosabb adatok
- Ki végzi
- BioAegis Therapeutics Inc.
- Hol
- Augusta, Chicago, Hannibal, Hershey, Houston, Los Angeles, Louisville, New York, Pittsburgh és Rochester (Egyesült Államok)Mind a 11 helyszín megnézéseMég 12 másik országban, 66 helyszínen
- Azonosító
- NCT05947955
- EU 2023-510109-16-00
- U1111-1305-2474
- Állapot
- Toboroz
- Fázis
- 2. fázis
- Résztvevők
- 600 fő, tervezett
- Kezdés
- 2024. okt. 3.
- Várható befejezés
- 2028. márc. 1.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
- A vizsgált kezelések
- Rhu-pGSN
- normal saline
- A regiszteradat frissítve
- 2026. október 20.
Ki vehet részt
- Életkor
- 18 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 19 feltétel megnézéseKevesebb
Ki vehet részt
- Infection followed within a week of documented bilateral infiltrates/opacities consistent with ARDS, as assessed by the admitting emergency department, clinic, intensivist, or ward physician or equivalent caregiver or a radiologist; Investigator or designee to note radiologic findings in the electronic case report form (eCRF); Radiology report and conclusion should be summarized in the eCRF; A digital copy of the radiograph uploaded and saved for review
- Acute hypoxemic respiratory failure (moderate-to-severe ARDS) for ≤48 hours associated with suspected or confirmed infection (moderate-to-severe ARDS defined by the ratio of arterial pressure of O2 to the fraction of inspired O2 ≤150). Eligible subjects will be intubated for mechanical ventilation, receiving noninvasive ventilation by continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BiPAP), or on HFNO at least 30 L/min of 50% or greater inspired O2. Although it is expected that most eligible subjects will be receiving positive end-expiratory pressure (PEEP) or CPAP ≥5 cm H2O consistent with the original Berlin definition (ARDS Definition Task Force 2012), these measures will not be mandated as entry criteria
- Age ≥18 years
- Informed consent obtained from subject/next of kin/legal proxy
- Clear or convincing evidence of a precipitating infection during the 7 days preceding the diagnosis of ARDS in the judgement of the screening or primary care team
- During the course of the study starting at screening and for at least 3 months after their final study treatment:; Female subjects of childbearing potential must agree to use 2 medically accepted and approved birth control methods; Male subjects with a partner who might become pregnant must agree to use reliable forms of contraception (i.e., vasectomy, abstinence), or an acceptable method of birth control must be used by the partner; All subjects must agree not to donate sperm or eggs
Ki nem vehet részt
- Previous splenectomy
- Any vaccination in the previous 30 days
- Participation in an investigational clinical trial (e.g., device, drug, or biologic) in the previous 30 days
- Active underlying cancer or treatment with systemic chemotherapy or radiation therapy during the last 60 days or likely to require similar treatments during the ensuing 6 months
- Ongoing evidence or suspicion that heart failure, volume overload, pulmonary emboli, atelectasis, chronic lung disease, pleural effusion, cardiac tamponade, or constrictive pericarditis are materially contributing to the clinical or radiological findings bas assessed by the care team or Investigator; an echocardiogram is strongly recommended as part of standard care to exclude a significant contribution of systolic or diastolic heart failure and volume overload
- Presence of systemic fungal, yeast, parasitic, or mycobacterial infection
- Known allergy to study drug or excipients
- Transplantation of hematopoietic or solid organs, graft versus host disease, or post-transplant lymphoproliferative disease
- Unsuitable for study participation, in the opinion of the Investigator, because of chronic, severe, end-stage, or life-limiting underlying disease unrelated to current infection likely to interfere with management and assessment of ARDS, only comfort or limited (non-aggressive) care is to be given, or life expectancy <6 months unrelated to acute infection in the opinion of the Investigator
- Current or planned receipt of extracorporeal membrane oxygenation (ECMO)
- Pregnant or lactating women
- Weight >125 kg
- Chronic mechanical ventilation or dialysis
Helyszínek itt: Egyesült Államok
Még 12 másik országban, 66 helyszínen
- Wellstar MCG Augusta UniversityAugusta, Egyesült ÁllamokContact: Marti Farrough, RNRésztvevőt keres
- Northwestern University - Pulmonary and Critical Care MedicineChicago, Egyesült ÁllamokContact: Helen K Donnelly, MS, BSN, RN, CCRCRésztvevőt keres
- Hannibal Regional HospitalHannibal, Egyesült ÁllamokContact: Lindsey Gander, RN CRCRésztvevőt keres
- Penn State Health Milton S. Hershey Medical CenterHershey, Egyesült ÁllamokContact: Kylee KimbelRésztvevőt keres
- McGovern Medical School - UT Physicians Pulmonary Medicine - Texas Medical CenterHouston, Egyesült ÁllamokContact: Elizabeth VidalesRésztvevőt keres
- Cedars-Sinai Medical CenterLos Angeles, Egyesült ÁllamokContact: Vivian HweRésztvevőt keres
- University of Louisville Hospital - Jewish HospitalLouisville, Egyesült ÁllamokContact: Julie BurmesterRésztvevőt keres
- University of Louisville Jewish HospitalLouisville, Egyesült ÁllamokContact: Julie BurmesterRésztvevőt keres
- New York University Grossman School of MedicineNew York, Egyesült ÁllamokContact: Natalia LeontovichToborzás még nem indult
- University of Pittsburgh Medical CenterPittsburgh, Egyesült ÁllamokContact: Chelsea PeetRésztvevőt keres
- Mayo ClinicRochester, Egyesült ÁllamokContact: Amy SchuchardRésztvevőt keres
A vizsgálatról
Mit akar kideríteni a vizsgálat
BTI-203 is a randomized, double-blind, placebo-controlled, multicenter, Phase 2 proof-of-concept (POC) study to evaluate the efficacy and safety of rhu-pGSN plus standard of care (SOC) in subjects with moderate-to-severe ARDS (P/F ratio ≤150) due to pneumonia or other infections. Potential subjects hospitalized with pneumonia or other infections are to be screened within 24 hours of diagnosis of ARDS.
A vizsgálat 2 csoportja
- Rhu-pGSN TreatmentA vizsgált kezelés
Subjects will receive rhu-pGSN 24 mg/kg once, followed by 5 daily doses of 12 mg/kg based on actual body weight in addition to standard care .
Kezelés: Rhu-pGSN
- Normal Saline PlaceboPlacebo, összehasonlításként
Subjects will receive 6 doses of normal-saline placebo in volumes equivalent to subjects given rhu-pGSN in addition to standard care.
Kezelés: normal saline
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on és az EU hivatalos vizsgálati nyilvántartásában (CTIS).
- Hivatalos cím
- A Phase 2 Randomized Double-blind Placebo-controlled Study To Evaluate The Efficacy And Safety Of Adjunctive Recombinant Human Plasma Gelsolin With Standard Care For Moderate-to-Severe ARDS Due To Pneumonia Or Other Infections
- A regiszteradat frissítve
- 2026. október 20.